Related references
Note: Only part of the references are listed.Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non-Small-Cell Lung Cancer
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Disrupting Established Tumor Blood Vessels An Emerging Therapeutic Strategy for Cancer
Mark J. McKeage et al.
CANCER (2010)
Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC
Roberto Pili et al.
CLINICAL CANCER RESEARCH (2010)
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
Mark J. McKeage et al.
LUNG CANCER (2009)
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
M. J. McKeage et al.
BRITISH JOURNAL OF CANCER (2008)
Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients
Jing Li et al.
CLINICAL CANCER RESEARCH (2008)
Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial
M. B. Jameson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent
M McKeage et al.
CLINICAL CANCER RESEARCH (2006)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
MB Jameson et al.
BRITISH JOURNAL OF CANCER (2003)
5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
GJS Rustin et al.
BRITISH JOURNAL OF CANCER (2003)
6-Methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3
SF Zhou et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2002)
Identification and reactivity of the major metabolite (β-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans
SF Zhou et al.
XENOBIOTICA (2001)
Share Paper
